[Dyslipidemia in uremic patients at the National Hospital of Donka-Conakry]

Related Experiment Video

Updated: Jun 23, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

M L Kaba, M Diakite, A O Bah

    Le Mali Medical
    |May 15, 2009
    PubMed

    Insights

    Dyslipidemia is common in chronic renal failure (CRF) patients. This study found high prevalence of lipid abnormalities and cardiovascular risk factors in non-dialyzed and dialyzed CRF patients.

    Area of Science:

    • Nephrology
    • Cardiology
    • Clinical Biochemistry

    Context:

    • Patients with chronic renal failure (CRF) exhibit higher dyslipidemia prevalence than the general population.
    • Advanced CRF, defined as creatinine clearance < 30 ml/mn, and hemodialysis patients were included.
    • Cardiovascular disease is a significant concern in patients with kidney disease.

    Purpose:

    • To determine the prevalence of dyslipidemia and lipid anomalies in uremic patients.
    • To evaluate associated cardiovascular risk factors in this population.
    • To compare lipid profiles and risk factors between dialyzed and non-dialyzed CRF patients.

    Summary:

    • The study included 60 patients with advanced CRF. Lipid disturbances were observed in 56% of dialyzed and 70% of non-dialyzed patients.
    • Hypertriglyceridemia was the most common anomaly, followed by mixed hyperlipidemia and low HDL cholesterol.
    • Associated cardiovascular risk factors included hypertension (noted in 9 dialyzed and 20 non-dialyzed patients) and diabetes (observed in 1 and 3 patients, respectively). Smoking was also prevalent.

    Impact:

    • Findings highlight the high burden of dyslipidemia and cardiovascular risk in CRF patients.
    • The study underscores the need for proactive management of lipid profiles and cardiovascular risk factors in this vulnerable population.
    • Results can inform clinical guidelines and patient care strategies for managing CRF patients.

    Related Concept Videos

    Chronic Kidney Disease II: Clinical Manifestations01:24

    Chronic Kidney Disease II: Clinical Manifestations

    Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
    Chronic Kidney Disease III: Interprofessional Care01:28

    Chronic Kidney Disease III: Interprofessional Care

    Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
    Nephrotic Syndrome I : Introduction01:24

    Nephrotic Syndrome I : Introduction

    Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
    Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

    Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

    In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
    Nephrotic Syndrome II : Assessment and Medical Management01:26

    Nephrotic Syndrome II : Assessment and Medical Management

    IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
    Chronic Kidney Disease IV: Nursing Management01:18

    Chronic Kidney Disease IV: Nursing Management

    Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...